media – Page 4 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Singapore approves CMS’s ruxolitinib phosphate cream for nonsegmental vitiligo

China Medical System (00867.HK) announced on November 4 that Singapore’s Health Sciences Authority had approved Lumirix® (ruxolitinib phosphate cream) for nonsegmental vitiligo with facial involvement in adults and adolescents aged 12 and older. According to the company, it was Singapore’s first and, at the time, only topical prescription treatment that directly targets the underlying disease mechanism. Source: http://finance.eastmoney.com/a/202611043922060662.html
- Source: drugdu
- 94
- November 6, 2026
China accepts United Laboratories’ semaglutide injection filing for weight management

The United Laboratories (03933) announced on November 4 that China’s NMPA had accepted a marketing application from its wholly owned Zhuhai biologics subsidiary for semaglutide injection for weight management. The article describes uses of semaglutide injection in glycemic control in type 2 diabetes, long-term weight management in people with obesity or overweight, and reducing the risk of related cardiovascular events. The United Laboratories said the filing broadens its planned indications for the product. Its GLP-1 pipeline includes both innovative drugs and biosimilars. Source: http://finance.eastmoney.com/a/202611053922758066.html
- Source: drugdu
- 124
- November 6, 2026
Daridorexant receives US FDA Breakthrough Therapy designation for pediatric insomnia

According to Simcere Pharmaceutical on November 5, the US FDA granted daridorexant Breakthrough Therapy designation for insomnia disorder in children and adolescents aged 10 to 18. The article cites study findings that the 50 mg dose showed a safety profile similar to placebo, with no drug abuse-related adverse events reported during treatment. Daridorexant is a dual orexin receptor antagonist that suppresses wake-promoting signaling by blocking orexin A and B from binding to their receptors. In November 2022, Simcere obtained exclusive development and commercialization rights in Greater China from Switzerland’s Idorsia. China approved the drug in June 2025 for adults with insomnia characterized by difficulty falling or staying asleep. Source: http://finance.eastmoney.com/a/202611053923706422.html
- Source: drugdu
- 100
- November 6, 2026
Menovo subsidiary passes first US FDA on-site inspection for tildipirosin API

Menovo (603538) disclosed on November 6 that its controlled subsidiary, Xuancheng Menovo, received a US FDA inspection report on November 4 confirming that it had passed its first FDA on-site inspection for tildipirosin API. The preapproval cGMP inspection ran from June 22 to 26, 2026, and covered quality, materials, manufacturing, facilities and equipment, packaging and labeling, and laboratory controls. The company said the inspection outcome would support its international expansion. Menovo develops, manufactures and sells specialty APIs and finished dosage forms. In the first nine months of 2026, revenue rose 29.00% year on year to RMB 1.441 billion, and net profit attributable to shareholders rose 8.54% to RMB 104 million. Source: http://finance.eastmoney.com/a/202611063924413520.html
- Source: drugdu
- 94
- November 6, 2026
Grand Pharma’s investigational eye drop meets primary endpoint in global Phase III trial

Grand Pharma (00512.HK) announced on November 5 that CBT-001 (GPN00153), an investigational eye drop, met the primary endpoint in a multinational, multicenter Phase III trial for pterygium. The company reported efficacy at both doses and statistically significant improvements in redness and lesion size. The findings could support a future marketing application. CBT-001 is a multikinase inhibitor designed to target fibrovascular growth by blocking pathways involved in angiogenesis and fibrosis. Earlier studies reported sustained reductions in vascular growth and redness, with a favorable safety profile. The article also discusses potential use across disease severities and in preventing postoperative recurrence. Pterygium can grow from the conjunctiva onto the cornea and impair vision. The article reports that no drug had been approved specifically for the condition and cites a postoperative recurrence range of 31% to 83% and a global prevalence estimate of 10.2%. Frost & Sullivan estimated that the global patient population would ...
- Source: drugdu
- 77
- November 6, 2026
Hunan Warrant Pharmaceutical subsidiary wins approval for esomeprazole magnesium API

Hunan Warrant Pharmaceutical (688799) disclosed on the evening of November 5 that China’s National Medical Products Administration (NMPA) had approved the marketing application for esomeprazole magnesium active pharmaceutical ingredient (API) from its wholly owned chiral pharmaceuticals subsidiary. The API is used in formulations including gastro-resistant esomeprazole magnesium capsules. The filing lists gastroesophageal reflux disease, eradication of Helicobacter pylori in combination with appropriate antibacterial therapy, and use in patients who require ongoing nonsteroidal anti-inflammatory drug therapy. Source: http://finance.eastmoney.com/a/202611053923758717.html
- Source: drugdu
- 85
- November 6, 2026
BioPlus-Interphex Korea

Organiser：Reed Exhibitions Group Time：October 28th – October 30th, 2026 Address：513 Yeongdong-daero, Gangnam District, Seoul, South Korea Exhibition hall：COEX Convention & Exhibition Center Product range: Pharmaceutical Raw Materials and Ingredients: APIs, intermediates, additives, functional raw materials, natural extracts, fine chemicals, business outsourcing, contract processing, OEM formulations Biopharmaceuticals: Laboratory equipment and reagents, biological preparations, drug R&D, biotechnology, genomics About BioPlus-Interphex Korea： BioPlus-Interphex Korea in Seoul, South Korea is a biopharmaceutical exhibition that showcases the “value chain of biopharmaceuticals” and proposes overseas expansion through the establishment of a global business network. It is a collaborative event between ‌KoreaBIO‌, the leading enterprise in South Korea’s bioindustry, and INTERPHEX, an international pharmaceutical exhibition brand. Aiming to enhance the brand value of South Korea’s bioindustry and actively engage in exchanges with the global market, BioPlus-Interphex Korea has been hosted by the Korea Bio Industry Association since 2015. It covers R&D technologies, manufacturing technologies and ...
- Source: drugdu
- 76
- November 5, 2026
Azithromycin Dispersible Tablets (0.25g) from Shijiazhuang No. 4 Pharmaceutical Group have passed the quality assessment.

On November 3, Shijiazhuang No. 4 Pharmaceutical Group’s azithromycin dispersible tablets (0.25g) received the “Approval Notice for Supplementary Drug Application” from the National Medical Products Administration, passing the consistency evaluation of generic drug quality and efficacy. This is another new achievement for the group in the field of oral anti-infective preparations.It is understood that azithromycin dispersible tablets are a macrolide antibiotic, mainly used for respiratory tract infections, skin and soft tissue infections and other diseases caused by susceptible strains.Leveraging its integrated “API + formulation” industrial layout, the group has established a significant differentiated competitive advantage in its azithromycin product chain. Previously, the company’s azithromycin dry suspension, azithromycin tablets, and azithromycin for injection (lyophilized powder for injection) dosage forms had passed or were deemed to have passed the consistency evaluation. With the approval of the azithromycin dispersible tablets, the group has not only further enriched its azithromycin formulation product chain but ...
- Source: drugdu
- 82
- November 4, 2026
The stock price plummeted 90% after the Phase 2 clinical trial failed

Recently, biopharmaceutical company Acumen Pharmaceuticals announced the results of its global Phase 2 clinical trial ALTITUDE-AD for its investigational Alzheimer’s disease candidate Sabirnetug (ACU193) : the trial failed to meet the primary endpoint, and the company immediately announced the termination of drug development. The stock price of Acumen Pharmaceuticals fell by about 90% that day . Sabirnetug is a humanized monoclonal antibody whose mechanism of action is not to directly clear amyloid plaques, but rather to selectively target soluble amyloid β-oligomers . These oligomers are considered to have strong neurotoxicity and may be involved in the neurodegenerative process of Alzheimer’s disease at an earlier stage. The drug had previously received Fast Track designation from the U.S. FDA . The ALTITUDE-AD study included 542 patients with early-stage Alzheimer’s disease, covering multiple centers in the United States, Canada, the European Union, and the United Kingdom. The primary endpoint was the change in ...
- Source: drugdu
- 105
- November 4, 2026
United Imaging Healthcare enters a period of transition.

Recently, United Imaging Healthcare released its Q3 2026 financial report, showing continued revenue growth and a rapid recovery in profitability. Restore double growth Overseas markets are growing rapidly. From a revenue perspective, United Imaging Healthcare’s revenue performance continued to improve in the first three quarters of 2026, showing a significant quarter-on-quarter upward trend, with a cumulative revenue of RMB 10.58 billion. Among them, the revenue in the third quarter alone reached RMB 3.529 billion, with a year-on-year increase of 24.12%. A horizontal comparison of the first two quarters (Q1 revenue of RMB 2.908 billion, up 17.34% year-on-year; Q2 revenue of RMB 4.144 billion, up 17.13% year-on-year) shows that the revenue growth rate in Q3 accelerated significantly , and the overall revenue curve maintained a steady upward trend. On the profit front, there were stronger signs of marginal improvement, with net profit attributable to the parent company reaching RMB 138 million ...
- Source: drugdu
- 84
- November 4, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.